Quadrant Biosciences Receives Breakthrough Device Designation for Novel Autism Saliva Test
Quadrant Biosciences Receives Breakthrough Device Designation for Novel Autism Saliva Test News provided by Share this article Share this article SYRACUSE, N.Y., April 19, 2021 /PRNewswire/ -- Quadrant Biosciences Inc., a developer of novel molecular diagnostic tools, has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its innovative Clarifi ASD® autism saliva test. Clarifi ASD is indicated for use in assessing the likelihood that a child has autism spectrum disorder (ASD) based on an evalu...